CYRX Cryoport, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1124524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.8%
TTM net income YoY-157.9%
TTM EPS YoY-178.6%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—
Margins
Gross margin46.9%
Operating margin-20.0%
Net margin-21.5%
FCF margin-9.8%
EBITDA margin-6.6%
Returns
ROE-8.3%
ROA-5.4%
ROIC (approx.)-13.2%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets35.6%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-18.32x
Cash quality & payout
Operating cash flow / net income-0.27x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue15.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20202021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $176.18M | $156.77M | $168.66M | $237.28M | $222.61M |
| Cost of revenue | $93.12M | $87.11M | $93.33M | $133.40M | $126.03M |
| Gross profit | $83.05M | $69.66M | $75.33M | $103.87M | $96.58M |
| R&D expense | $17.04M | $17.71M | $18.04M | $15.72M | $16.84M |
| SG&A expense | $102.82M | $109.81M | $108.26M | $120.06M | $97.56M |
| Operating income | -$36.81M | -$121.67M | -$100.54M | -$31.90M | -$17.83M |
| Interest expense | $2.36M | $3.98M | $5.58M | $6.14M | $4.69M |
| Pretax income | -$32.17M | -$104.35M | -$84.21M | -$35.09M | -$273.84M |
| Income tax | $1.80M | $359,000 | $345,000 | $2.24M | $1.69M |
| Net income | $78.30M | -$114.76M | -$99.59M | -$37.33M | -$275.53M |
| EBITDA | -$9.09M | -$90.91M | -$73.05M | -$9.14M | $2.42M |
| EPS (basic) | 1.40 | -2.49 | -2.21 | -0.93 | -6.18 |
| EPS (diluted) | 1.40 | -2.49 | -2.21 | -0.93 | -6.18 |
| Weighted avg. shares (diluted) | 50.07M | 49.35M | 48.74M | 48.99M | 45.93M |
| Banking | |||||
| Provision for credit losses | — | — | $822,000 | $234,000 | $26,000 |
| Balance sheet | |||||
| Cash & equivalents | $250.49M | $34.14M | $35.19M | $29.23M | $139.10M |
| Short-term investments | $160.71M | $216.46M | $410.41M | $486.73M | $489.70M |
| Receivables | $33.36M | $25.30M | $42.07M | $43.86M | $39.41M |
| Inventory | $23.19M | $21.48M | $26.21M | $27.68M | $16.50M |
| Current assets | $476.17M | $341.57M | $535.11M | $604.18M | $693.52M |
| PP&E, net | $85.45M | $80.01M | $84.86M | $63.60M | $49.03M |
| Goodwill | $22.40M | $20.57M | $76.39M | $151.12M | $146.95M |
| Intangibles | $138.08M | $147.93M | $194.38M | $191.01M | $201.43M |
| Total assets | $764.99M | $703.49M | $957.74M | $1.04B | $1.11B |
| Current liabilities | $219.02M | $64.56M | $45.61M | $40.85M | $42.65M |
| Total liabilities | $262.35M | $301.59M | $468.72M | $482.91M | $471.14M |
| Shareholders' equity | $502.64M | $401.90M | $489.02M | $555.84M | $641.83M |
| Shares outstanding | 49.85M | 49.91M | 48.97M | 48.33M | 49.62M |
| Cash flow statement | |||||
| Operating cash flow | -$8.58M | -$16.32M | -$757,000 | -$1.85M | $8.13M |
| Capital expenditure | $16.44M | $17.25M | $38.78M | $22.11M | $23.88M |
| Free cash flow | -$25.02M | -$33.58M | -$39.54M | -$23.96M | -$15.76M |
| Investing cash flow | $250.32M | $176.81M | $36.05M | -$59.68M | -$469.25M |
| Financing cash flow | -$21.07M | -$161.53M | -$23.80M | -$39.17M | $564.34M |
| Depreciation & amortization | $27.71M | $30.76M | $27.49M | $22.77M | $20.25M |
| Stock-based compensation | $10.07M | $16.57M | $19.82M | $20.08M | $15.35M |
| Share buybacks | $10.01M | — | — | $37.96M | $0 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.